TrialCancer chemotherapy and pharmacology2023

A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.

Pau Montesinos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.